Compare Novartis with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PROCTER & GAMBLE HEALTH - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PROCTER & GAMBLE HEALTH NOVARTIS/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 2,118.9 47.3 4,479.5% View Chart
P/BV x 28.1 5.1 556.8% View Chart
Dividend Yield % 1.6 9.4 16.7%  

Financials

 NOVARTIS   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    NOVARTIS
Mar-19
PROCTER & GAMBLE HEALTH
Dec-18
NOVARTIS/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs9803,549 27.6%   
Low Rs6001,301 46.1%   
Sales per share (Unadj.) Rs198.7511.4 38.9%  
Earnings per share (Unadj.) Rs21.061.3 34.2%  
Cash flow per share (Unadj.) Rs22.374.0 30.1%  
Dividends per share (Unadj.) Rs10.00440.00 2.3%  
Dividend yield (eoy) %1.318.1 7.0%  
Book value per share (Unadj.) Rs307.5927.8 33.1%  
Shares outstanding (eoy) m24.6916.60 148.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.7 83.8%   
Avg P/E ratio x37.739.6 95.2%  
P/CF ratio (eoy) x35.532.8 108.3%  
Price / Book Value ratio x2.62.6 98.3%  
Dividend payout %47.7717.9 6.6%   
Avg Mkt Cap Rs m19,50840,257 48.5%   
No. of employees `0000.61.1 51.2%   
Total wages/salary Rs m1,1711,313 89.2%   
Avg. sales/employee Rs Th8,445.47,486.7 112.8%   
Avg. wages/employee Rs Th2,015.71,157.6 174.1%   
Avg. net profit/employee Rs Th891.0897.2 99.3%   
INCOME DATA
Net Sales Rs m4,9078,490 57.8%  
Other income Rs m783244 320.9%   
Total revenues Rs m5,6898,734 65.1%   
Gross profit Rs m1231,482 8.3%  
Depreciation Rs m32211 15.1%   
Interest Rs m160-   
Profit before tax Rs m8581,514 56.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m340563 60.4%   
Profit after tax Rs m5181,017 50.9%  
Gross profit margin %2.517.5 14.3%  
Effective tax rate %39.637.1 106.7%   
Net profit margin %10.612.0 88.0%  
BALANCE SHEET DATA
Current assets Rs m8,05515,343 52.5%   
Current liabilities Rs m1,8501,960 94.4%   
Net working cap to sales %126.4157.6 80.2%  
Current ratio x4.47.8 55.6%  
Inventory Days Days4549 92.4%  
Debtors Days Days3428 119.2%  
Net fixed assets Rs m1501,209 12.4%   
Share capital Rs m123166 74.3%   
"Free" reserves Rs m7,46915,235 49.0%   
Net worth Rs m7,59215,401 49.3%   
Long term debt Rs m00-   
Total assets Rs m9,82417,595 55.8%  
Interest coverage x54.9NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.50.5 103.5%   
Return on assets %5.45.8 93.9%  
Return on equity %6.86.6 103.2%  
Return on capital %11.510.3 112.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m581,636 3.5%   
Fx outflow Rs m1,3264,368 30.4%   
Net fx Rs m-1,269-2,732 46.4%   
CASH FLOW
From Operations Rs m-1,943-1,304 149.0%  
From Investments Rs m2,74212,697 21.6%  
From Financial Activity Rs m-298-301 99.2%  
Net Cashflow Rs m50111,093 4.5%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 2.0 18.2 11.0%  
FIIs % 1.6 1.0 160.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 29.1 73.9%  
Shareholders   41,647 28,591 145.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   SUVEN LIFESCIENCES  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; Telecom and Healthcare Stocks Witness Selling(Closing)

Indian share markets erased the opening gains and ended marginally lower for the second consecutive day today.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

More Views on News

Most Popular

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

Is It Time to Book Profits in Gold and Silver?(Fast Profits Daily)

Aug 10, 2020

Gold and silver have delivered phenomenal returns this year. Is it time to take some money of the table?

Forget the Nifty and Sensex for the Next 1 or 2 Years and Focus on These Stocks(Profit Hunter)

Aug 6, 2020

Stocks from the essential small cap space are likely to be outperformers over the next 1 or 2 years.

This 20 Year Cycle Suggests Gold is Set for an August Rally(Profit Hunter)

Jul 31, 2020

The real reason why gold prices will go up more.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 13, 2020 03:37 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - AUROBINDO PHARMA COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS